drugset / Trial / NCT03869632
First in Human Dose Escalation Study of YL-13027 in Subjects With Advanced Stage Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
YL-13027-001 is a phase I open-label, first in human, dose escalation study which investigate the tolerability, safety, pharmacokinetics (PK) and efficacy of YL-13027 in subjects with advanced stage solid tumors.
Timeline
- Start
- 2019-03-19
- Primary completion
- 2021-04-30
- Completion
- 2022-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | YL-13027 | Small molecule | 60 mg | Oral |
| Subject | YL-13027 | Small molecule | 360 mg | Oral |